Allogene executive plans sale of 35,700 shares

Allogene Therapeutics insider Zachary Roberts has filed a Form 144 notice to sell 35,700 shares of common stock, with an aggregate market value of $63,353.22, through Morgan Stanley Smith Barney on NASDAQ around February 2, 2026.

Rhea-AI Filing Summary

Allogene Therapeutics insider Zachary Roberts has filed a Form 144 notice to sell 35,700 shares of common stock, with an aggregate market value of $63,353.22, through Morgan Stanley Smith Barney on NASDAQ around February 2, 2026.

The shares were acquired on January 31, 2026 via restricted stock vesting under a registered compensation plan, with 224,730,144 common shares outstanding. In the prior three months, Roberts sold 26,269 common shares for gross proceeds of $40,979.64. The filer represents they are not aware of undisclosed material adverse information about Allogene.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Allogene (ALLO) Form 144 filed by Zachary Roberts disclose?

The Form 144 shows Zachary Roberts plans to sell 35,700 Allogene common shares on NASDAQ, valued at about $63,353.22. The shares came from restricted stock vesting under a registered compensation plan on January 31, 2026.

How many Allogene (ALLO) shares are outstanding in this Form 144?

The filing states there are 224,730,144 Allogene common shares outstanding. This figure provides context for the planned sale of 35,700 shares under Rule 144 and helps investors see how small the transaction is relative to total shares.

What prior Allogene (ALLO) stock sales by Zachary Roberts are reported?

Over the past three months, Zachary Roberts sold 26,269 Allogene common shares for gross proceeds of $40,979.64. This historical sale information is required in the Form 144 to show recent selling activity by the same person.

How were the Allogene (ALLO) shares in this Form 144 acquired?

The 35,700 shares were acquired as restricted stock vesting on January 31, 2026 under a registered equity compensation plan. The filing lists the issuer as the source and identifies the consideration as compensation, not a cash purchase.

Which broker and exchange are used for this Allogene (ALLO) Form 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ exchange. The Form 144 lists the broker’s New York address and an approximate sale date of February 2, 2026.

What representation does the seller make in the Allogene (ALLO) Form 144?

By signing the notice, the seller represents they do not know any material adverse information about Allogene’s current or prospective operations that has not been publicly disclosed, as required for sales relying on Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001851044
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ALLOGENE THERAPEUTICS, INC.
SEC File Number	001-38693
Address of Issuer	210 East Grand Avenue South San Francisco CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	ZACHARY J ROBERTS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	35700	63353.22	224730144	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/31/2026	Restricted stock vesting under a registered plan	Issuer			35700	01/31/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Zachary Roberts 210 East Grand Avenue South San Francisco CA 94080	Common	01/21/2026	26269	40979.64

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Zachary Roberts
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)